Treatment with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF), a widely used, potent regimen is sometimes restricted by the myelotoxicity and myocardiotoxicity of adriamycin (ADR). In a prospective randomized controlled study of patients with advanced or recurrent breast cancer, the efficacy and toxicity of a CEF regimen, in which epirubicin (EPI) was substituted for ADR, was compared with CAF.
138 female patients under 75 years of age who had unresectable or recurrent breast cancer during the period from October, 1989 to September, 1991, were randomized to one of two treatment regimens. The first regimen consisted of cyclophosphamide 100 mg p.o. d1-14, adriamycin 30 mg/mp2 i.v. d1, 8 and 5-fluorouracil 500 mg/mp2 i.v. d1, 8 (CAF). In the second regimen, EPI 30 mg/mp2 i.v. d1, 8 was substituted for ADR (CEF). Both regimens were delivered q4 weeks.
Of 138 patients, 105 (CEF 56, CAF 49) were evaluable for response and survival, and all were evaluable for toxicity (CEF 68, CAF 70). The median course of lots CEF and CAF was 3 cycles. Response rates (complete response plus partial response) with CEF and CAF were 35.7% (20/56) and 36.7% (1 8/49), respectively. Adverse effects were similar in the two groups, but severe leukopenia (CEF 36.8%, CAF 64.3%) and hepatic toxicity (CEF 1.5%, CAF 12.9%) were encountered more frequently with CAF than with CEF. The duration of 50% survival was 135.9 weeks for CEF and 172.1 weeks for CAF (not significant).
At an equal dose of EPI and ADR response rates and survival of the CEF group were similar to those of the CAF group, but adverse effects were fewer in the CEF group.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Cyclophosphamide, adriamycin, and 5-fluorouracil
Cyclophosphamide, epirubicin, and 5-fluorouracil
White blood cell
Preiffer P, Cold S, Rose C: Cytotoxic treatment of metastatic breast cancer; Which drugs and drug combinations to use?Acta Oncol 31:219–224, 1992.
Mouridsen HT: Systemic therapy of advanced breast cancer.Drugs 44 (suppl 4): 17–28, 1992.
Bull JM, Tormey DC, Li SH,et al: A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy.Cancer 41:1649–1657, 1978.
Traum B, Hoogstrateu B, Kennedy A,et al: Adriamycin in combination for the treatment of breast cancer.Cancer 41:2078–2083, 1978.
Hortobagyi GN, Bodey GP, Buzdar AU,et al: Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units; A prospective randomized study.J Clin Oncol 5:354–364, 1987.
Cummings FJ, Gelman R, Horton J: Comparison of CAF versus CMFP in metastatic breast cancer; Analysis of prognostic factors.J Clin Oncol 3:939–940, 1985.
Aisner J, Weinberg V, Perloff M,et al: Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF Each ± MER) for metastatic carcinoma of the breast; A CALGB study.J Clin Oncol 5:1523–1533, 1987.
Falkson G, Tormey DC, Carey P,et al: Long-term survival of patients treated with combination chemotherapy for metastatic breast cancer.Eur J Cancer 27:973–977, 1991.
Kubo K, Abe O, Izuo M,et al: Clinical evaluation of adriamycin for advanced breast cancer (No. 3); A join study by 26 institutes on the CAF and CMcF regimens.Jpn J Cancer Chemother 10:2523–2531, 1983.
Casazza MA, Giuliani FC: Preclinical properties of epirubicin. In: Bonadonna G ed, Advances in Anthracycline Chemotherapy; Epirubicin, Masson Italia Editori, Milano, pp 31–40, 1984.
Ganzina F: 4-Epi-doxorubicin, a new analogue of doxorubicin; A preliminary overview of preclinical and clinical data.Cancer Treat Rev 10:1–22, 1983.
Japan Society For Cancer Therapy: Criteria for the evaluation of the clinical effects of solid cancer chemotherapy.J Jpn Soc Cancer Ther 28:101–130, 1993.
The Italian multicentre breast study with epirubicin: Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer; An Italian multicentre trial.J Clin Oncol 6:976–982, 1988.
The French Epirubicin Study Group: A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin.J Clin Oncol 6:679–688, 1988.
Mouridsen HT, Alfthan C, Bastholt L,et al: Current status of epirubicin (Farmorubicin) in the treatment of solid tumours.Acta Oncol 29:257–285, 1990.
Tominaga T, Abe O: Retrospective study on adriamycine chemotherapy in Japanese breast cancer patients.Jpn J Cancer Chemother 7:852–860, 1980.
Aisner J, Cirrincione C, Perloff M,et al: Combination chemotherapy for metastatic or recurrent carcinoma of the breast; A randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP; Cancer and leukemia group B study 8281.J Clin Oncol 13:1443–1452, 1995.
Perry MC, Kardinal CG, Korzum AH,et al: Chemohormonal therapy in advanced carcinoma of the breast; Cancer and leukemia group B protocol 8081.J Clin Oncol 5:1534–1545, 1987.
Patterson AH, Zuck VP, Szafran O,et al: Influence and significance of certain prognostic factors on survival in breast cancer.Eur J Clin Oncol 18:937–943, 1982.
Hortobagyi GN, Smith TN, Legha SS,et al: Multivariate analysis of prognostic factors in metastatic breast cancer.J Clin Oncol 1:776–786, 1983.
Falkson G, Gelman RS, Pretorius FJ: Age as a prognostic factor in recurrent breast cancer.J Clin Oncol 4:663–671, 1986.
About this article
Cite this article
Kobayashi, T., Koyama, H., Oka, T. et al. Prospective randomized study of cyclophosphamide, epirubicin, and 5-fluorouracil versus cyclophosphamide, adriamycin, and 5-fluorouracil in advanced or recurrent breast cancer. Breast Cancer 6, 37 (1999). https://doi.org/10.1007/BF02966904
- Breast cancer